BFRI - Biofrontera gains on patent win for photodynamic therapy

Biofrontera (BFRI +28.3%) is surging in the pre-market after announcing that the U.S. regulators issued a Notice of Allowance for a patent covering the photodynamic therapy (PDT), a focus area for the biopharma company. The U.S. patent application number 17/234,490 titled “Illumination for Photodynamic Therapy,” related to the pain-reducing illumination protocol for photodynamic therapy (PDT), a statement from Biofrontera (NASDAQ:BFRI) read. The company expects that a software installation will be enough to incorporate the new protocol in its medical devices. Biofrontera’s FDA-approved drug Ameluz is used to treat the precancerous skin condition, actinic keratoses (AK) in combination with its BF-RhodoLED lamp and PDT. A Phase 3 trial is expected to start in 2022 to include the protocol in the U.S. prescribing information.

For further details see:

Biofrontera gains on patent win for photodynamic therapy